1. Introduction {#sec1}
===============

Pituitary apoplexy is a life-threatening clinical syndrome thought to be attributable to hemorrhage or hemorrhagic infarction of pituitary tumors or pituitary glands \[[@B21]\]. Suggested precipitating factors are hypertension, anticoagulation, and bromocriptine therapy, and pregnancy \[[@B1]--[@B29]\]. There are few reports on the occurrence of pituitary apoplexy as a complication of the endocrine stimulation test, and its features remain to be elucidated. We report two rare patients with pituitary apoplexy associated with the endocrine stimulation test who were treated successfully by surgery and present a review of the literature. We also discussed about the necessity of neurosurgical support.

2. Case Presentation {#sec2}
====================

2.1. Case 1 {#sec2.1}
-----------

A 56-year-old woman with a one-year history of visual disturbance was admitted to our hospital for the evaluation of a suprasellar tumor. Physical examination at admission revealed visual disturbance (temporal hemianopia on the left side) but no other neurological disorders or endocrinological symptoms. Her baseline levels of pituitary hormones were normal. Computed tomography (CT) and magnetic resonance imaging (MRI) studies demonstrated a pituitary adenoma with suprasellar extension and superior displacement of the optic chiasm. To evaluate her hormonal responses we performed combined endocrine stimulation tests with growth-hormone-releasing hormone (GRH, 100 *μ*g), thyrotropin-releasing hormone (TRH, 250 *μ*g), luteinizing hormone-releasing hormone (LH-RH, 100 *μ*g), and corticotrophin-releasing hormone (CRH, 100 *μ*g). Fifteen minutes after the intravenous bolus injection she complained of severe headache, and this was followed by vomiting, progressive visual disturbance, and left oculomotor paralysis. She was alert but her symptoms gradually worsened. Emergency CT and MRI revealed intratumoral hemorrhage (Figures [1(a)](#fig1){ref-type="fig"}--[1(d)](#fig1){ref-type="fig"}). Four hours after onset, her left visual acuity was reduced to total blindness; there was temporal hemianopia in the right visual field. At emergency endoscopic endonasal transsphenoidal surgery was (ETSS) performed 5 hr after onset. Partially, tumor was solid and reddish-brown, different from the typical feature of pituitary adenoma. The tumor was totally removed. Pathological examination revealed hemorrhagic and necrotic area in nonnecrotic papillary-patterned tumor tissue ([Figure 1(e)](#fig1){ref-type="fig"}). Postoperatively, her headache, nausea and left oculomotor paralysis resolved, and her vision returned to the preonset level. Because of her diabetes insipidus (DI) she received transient desmopressin replacement therapy. She was able to resume her normal life.

2.2. Case 2 {#sec2.2}
-----------

A 73-year-old man with an 8-month history of visual disturbance was referred to our hospital. Five years earlier, when he was diagnosed with suprasellar tumor, he was asymptomatic and without visual disturbance. In the intervening five years, his tumor gradually enlarged and became symptomatic. At admission to our hospital, visual field examination revealed temporal hemianopia on the left side. He had no other neurological disorders or endocrinological symptoms. His baseline pituitary hormone levels were normal. CT and MRI demonstrated a pituitary adenoma with suprasellar extension and superior displacement of the optic chiasm. For preoperative endocrine evaluation we performed combined endocrine stimulation tests with growth hormone releasing peptide-2 (GHRP2, 100 *μ*g), TRH (250 *μ*g), LH-RH (100 *μ*g), and CRH (100 *μ*g). Twenty minutes after the intravenous bolus injection he complained of progressive visual disturbance. He was alert and experienced neither headache nor nausea. Emergency CT and MRI performed one hr after onset showed no evidence of intratumoral hemorrhage (Figures [2(a)](#fig2){ref-type="fig"}--[2(c)](#fig2){ref-type="fig"}), two hr after onset his left visual acuity was reduced to total blindness. There was no visual disturbance on the right side. He underwent ETSS 5 hr after onset, and the tumor was totally removed. Same as Case 1, tumor was partially solid and reddish-brown. Pathological examination revealed papillary-patterned adenoma with diffuse hemorrhage and necrosis ([Figure 2(d)](#fig2){ref-type="fig"}). His postoperative course was uneventful. One month after the operation his visual disturbance resolved completely, and he required no hormone replacement therapy.

3. Discussion {#sec3}
=============

Pituitary apoplexy is a rare clinical syndrome thought to be attributable to hemorrhage or hemorrhagic infarction of pituitary tumors or pituitary glands. It is characterized by the sudden onset of headache, vomiting, visual impairment, and decreased consciousness. Reported precipitating factors of pituitary apoplexy are hypertension, anticoagulation and bromocriptine therapy, pregnancy, and angiography \[[@B21], [@B24]\]. Although pituitary apoplexy associated with the endocrine stimulation test has been reported ([Table 1](#tab1){ref-type="table"}), its features remain to be elucidated \[[@B1]--[@B29]\]. Of the 32 previously-reported patients and our two patients with pituitary adenomas who experienced pituitary apoplexy, 16 (47%) had nonfunctioning, 8 (23.5%) GH-secreting, 5 (14.7%) prolactin (PRL)-secreting, 3 (8.8%) follicle-stimulating hormone (FSH)-secreting, and 2 (5.9%) had adrenocorticotropic hormone (ACTH)-secreting adenomas. This proportion is similar to the frequency among the types of pituitary adenomas \[[@B18]\]. This suggests that there is no strong correlation between the types of pituitary adenoma and the elicitation of pituitary apoplexy by the endocrine stimulation test. On the other hand, there appears to be a relationship between the size of pituitary adenomas and pituitary apoplexy associated with the endocrine stimulation test. Our review of the literature showed that 93% of previouslyn reported patients manifested extrasellar extension of their pituitary tumors. TRH (26 cases, 76.4%) and LH-RH (23 cases, 67.6%) were the hormonal stimulants most commonly associated with the elicitation of pituitary apoplexy. Although the precise mechanisms of pituitary apoplexy associated with TRH- and LH-RH stimulation remain unclear, it has been suggested that TRH elevates the serum level of norepinephrine, and that vasospasm or pressor effects may be precipitating factors \[[@B2], [@B15], [@B30]\]. Others proposed that TRH directly activates the tumor cells, or that LH-RH stimulation increases metabolic activity leading to vascular accidents \[[@B5], [@B12], [@B15], [@B19], [@B30]\]. Interestingly, the number of hormonal stimulants used in the endocrine stimulation test has no bearing on the elicitation of pituitary apoplexy; the Spearman correlation was *ρ* = − 0.40 with a *P* value of 0.6 ([Table 1(a)](#tab1){ref-type="table"}). Excluding the two patients reported here, the incidence of pituitary apoplexy among patients subjected to the endocrine stimulation test with four stimulants was 0 in our department. Because this test is convenient and the incidence of test-elicited pituitary apoplexy is low, it is used widely to investigate the reserve function of the pituitary in patients with pituitary adenoma. Nonetheless, based on earlier reports and our experience with the two patients reported here, we think that the necessity for performing the endocrine stimulation test must be evaluated on a case-by-case basis.

Among the 34 patients, detailed treatments and outcomes were available in 23 ([Table 1(b)](#tab1){ref-type="table"}); 20 patients underwent surgery, and the other 3 were treated conservatively \[[@B2], [@B3], [@B6], [@B7], [@B11], [@B13]--[@B15], [@B17]--[@B25], [@B28], [@B29], [@B30]\]. Of the latter, all experienced symptom exacerbation after suffering pituitary apoplexy \[[@B6], [@B7], [@B14], [@B23], [@B28]\]. Among the 20 surgically treated patients, in 14 the symptoms worsened after the occurrence of pituitary apoplexy while in the other six they were unchanged or improved \[[@B2], [@B3], [@B11], [@B13], [@B15], [@B17]--[@B22], [@B24], [@B25], [@B29], [@B30]\]. In three patients who underwent tumor removal on the day of onset of pituitary apoplexy, the symptoms were worse after than before onset while in another four they were improved or unchanged \[[@B2], [@B11], [@B15], [@B19], [@B30]\]. In our cases, the patients underwent surgery within 5 hr of apoplexy onset, the symptoms attributable to pituitary apoplexy were improved. Because pituitary apoplexy associated with the above-cited precipitating factors is rare, controversy continues to surround the standard treatment \[[@B21]\]. In some instances the symptoms associated with precipitating factors improved when surgery was performed within 7-8 days of apoplexy onset \[[@B21], [@B9]\].

Our review of the literature suggests that patients with pituitary apoplexy elicited by the endocrine stimulation test should be operated within several hours after its onset, that is, sooner than patients with pituitary apoplexy associated with the other precipitating factors. Performing only conservative treatment is not recommended. We recommend that the necessity for endocrine stimulation tests should be considered carefully and that they be performed with neurosurgical support.

![Case 1. CT scan performed 1 hr after onset demonstrates intratumoral hemorrhage (a), T1-weighted MRI showing a pituitary tumor extending into the suprasellar cistern (b), after onset gadolinium enhanced coronal T1-weighted MRI showing no enhancement of the pituitary tumor (c), T2-weighted MRI showing a pituitary tumor with a low-signal-intensity rim. This finding was suggestive of pituitary apoplexy (d), Specimen stained with hematoxylin and eosin. Hemorrhage and necrosis on the right side of the picture and area of nonnecrotic papillary-patterned tumor tissue on the left (e).](CRIM.ENDOCRINOLOGY2012-826901.001){#fig1}

![Case 2. CT scan performed 1 hour after onset demonstrates no evidence of intratumoral hemorrhage or acute enlargement of the tumor size (a), T1-weighted MRI performed after onset shows a pituitary tumor extending into the suprasellar cistern. There was no evidence of intratumoral hemorrhage or acute infarction (b), after onset gadolinium-enhanced T1-weighted MRI showing uniform enhancement of the pituitary tumor (c), and pathological examination revealed papillary-patterned adenoma with diffuse hemorrhage and necrosis (d).](CRIM.ENDOCRINOLOGY2012-826901.002){#fig2}

###### 

\(a\) Reported cases of pituitary apoplexy associated with endocrine stimulation test: diagnosis, extension, and stimulation test

  Case no.   Author             Year   Age/sex   Diagnosis        Extension               Stimulation test
  ---------- ------------------ ------ --------- ---------------- ----------------------- -----------------------------
  1          Dunn et al.        1975   22/F      GH secreting     Uncertain               TRH, glucose, insulin
  2          Silverman et al.   1978   31/M      PRL secreting    Extrasellar extension   Chlorpromazine
  3          Jordan et al.      1979   21/F      ACTH secreting   Uncertain               Dexamethasone
  4          Cimino et al.      1981   48/M      Nonfunctioning   Extrasellar extension   TRH, LH-RH
  5          Drury et al.       1982   59/F      Nonfunctioning   Extrasellar extension   TRH, LH-RH, glucagon
  6          Drury et al.       1982   66/M      GH secreting     Intrasellar             TRH
  7          Drury et al.       1982   39/F      PRL secreting    Extrasellar extension   TRH, LH-RH
  8          Drury et al.       1982   28/M      PRL secreting    Extrasellar extension   TRH, LH-RH
  9          Bernstein et al.   1984   48/M      Nonfunctioning   Extrasellar extension   TRH, LH-RH, insulin
  10         Korsic             1994   56/M      FSH secreting    Extrasellar extension   LH-RH
  11         Chapman et al.     1979   39/F      PRL secreting    Extrasellar extension   TRH, LH-RH, insulin
  12         Lever et al.       1986   19/F      GH secreting     Intrasellar             TRH
  13         Shirataki et al.   1988   50/F      GH secreting     Extrasellar extension   Bromocriptine
  14         Harvey et al.      1989   50/M      Nonfunctioning   Uncertain               Insulin
  15         Arafah et al.      1990   41/F      PRL secreting    Extrasellar extension   LH-RH
  16         Masson et al.      1993   54/F      FSH secreting    Extrasellar extension   LH-RH
  17         Okuda et al.       1994   60/F      Nonfunctioning   Extrasellar extension   TRH, LH-RH, insulin
  18         Vassallo et al.    1994   81/M      Nonfunctioning   Uncertain               TRH, LH-RH, L-Dopa
  19         Masago et al.      1995   48/M      FSH secreting    Extrasellar extension   TRH, LH-RH, insulin
  20         Masago et al.      1995   54/M      Nonfunctioning   Extrasellar extension   TRH, LH-RH
  21         Szabolcs et al.    1997   54/M      Nonfunctioning   Extrasellar extension   TRH
  22         Otsuka et al.      1998   31/F      GH secreting     Extrasellar extension   GRF, TRH, LH-RH, CRH
  23         Dökmetaş et al.    1999   28/F      GH secreting     Extrasellar extension   TRH
  24         Sanno et al.       1999   55/M      Nonfunctioning   Extrasellar extension   GRF, TRH, LH-RH, CRH
  25         Lee et al.         2000   34/M      GH secreting     Extrasellar extension   TRH, LH-RH, insulin
  26         Riedl et al.       2000   71/F      Nonfunctioning   Extrasellar extension   GRF, TRH, LH-RH, CRH
  27         Matsuura et al.    2001   63/M      Nonfunctioning   Extrasellar extension   TRH, LH-RH, insulin
  28         Rotman et al.      2003   19/F      ACTH secreting   Extrasellar extension   CRH
  29         Yoshino et al.     2007   36/M      Nonfunctioning   Extrasellar extension   TRH, LH-RH, insulin
  30         Yoshino et al.     2007   38/M      Nonfunctioning   Extrasellar extension   TRH, insulin
  31         Wang et al.        2007   41/F      GH secreting     Extrasellar extension   TRH, LH-RH, insulin, L-Dopa
  32         Kılıçlı et al.     2010   52/M      Nonfunctioning   Extrasellar extension   TRH, LH-RH, insulin
  33         Our cases          2011   56/F      Nonfunctioning   Extrasellar extension   GRF, TRH, LH-RH, CRH
  34         Our cases          2011   73/M      Nonfunctioning   Extrasellar extension   GHRP2, TRH, LH-RH, CRH

###### 

\(b\) Reported cases of pituitary apoplexy associated with endocrine stimulation test: treatment and outcomes of the 23 cases, for whom detailed treatments and outcomes were available

  Case no.   Treatment                 Interval from onset to surgery   Outcomes
  ---------- ------------------------- -------------------------------- ---------------------------------------------
  1          Medication                ---                              GH reduction, DI
  2          Craniotomy                Undocumented                     Panhypopituitarism
  3          Craniotomy                Undocumented                     Visual disturbance, hemiparesis, aphasia
  9          Transsphenoidal surgery   The same day (8.5 hours)         Visual disturbance, hemiparesis, aphasia
  11         Craniotomy                3 days later                     Recovered completely
  13         Transsphenoidal surgery   11 days later                    Recovered completely
  14         Transsphenoidal surgery   Undocumented                     Hypopituitarism
  17         Craniotomy                The same day and 17 days after   Recovered completely
  18         Medication                ---                              Hypopituitarism
  19         Craniotomy                The same day (7 hours)           Recovered completely
  20         Craniotomy                5 days later                     Hypopituitarism
  22         Transsphenoidal surgery   4 days later                     Hypopituitarism
  24         Transsphenoidal surgery   2 weeks later                    Hypopituitarism
  25         Transsphenoidal surgery   9 days later                     Hypopituitarism
  26         Transsphenoidal surgery   2 days later                     Visual disturbance, ophthalmoplegia
  27         Transsphenoidal surgery   1 day later (30 hours)           Improved to the level of preoperative state
  28         Medication                ---                              Hypopituitarism
  29         Transsphenoidal surgery   The same day and 21 days after   Hypopituitarism
  30         Transsphenoidal surgery   7 days later                     Hypopituitarism
  31         Transsphenoidal surgery   2 days later                     Ophthalmoplegia
  32         Transsphenoidal surgery   The same day                     Recovered completely
  33         Transsphenoidal surgery   The same day                     Visual disturbance
  34         Transsphenoidal surgery   The same day                     Recovered completely
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